CDKN2A / p16INK4a antibody [G175-405]
GTX01783
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetCDKN2A
Overview
- SupplierGeneTex
- Product NameCDKN2A / p16INK4a antibody [G175-405]
- Delivery Days Customer9
- Application Supplier NoteIHC-P: 1:100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDG175-405
- ConjugateUnconjugated
- Gene ID1029
- Target nameCDKN2A
- Target descriptioncyclin dependent kinase inhibitor 2A
- Target synonymsARF, CAI2, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16, cyclin-dependent kinase inhibitor 2A, CDK4 inhibitor p16-INK4, CDKN2A/ARF Intron 2 lncRNA, alternative reading frame, cell cycle negative regulator beta, cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), inhibitor of cdk4 A, multiple tumor suppressor 1, multiple tumour suppressor 1
- HostMouse
- IsotypeIgG1
- Protein IDP42771
- Protein NameCyclin-dependent kinase inhibitor 2A
- Scientific DescriptionThis gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Penciu RC, Postolache I, Steriu L, et al. Is there a relationship in-between ovarian endometriosis and ovarian cancer? Immunohistochemical profile of four cases with coexisting ovarian endometriosis and cancer. Rom J Morphol Embryol. 2020,61(1):157-165. doi: 10.47162/RJME.61.1.18Read this paper
- Wurlitzer M, Möckelmann N, Kriegs M, et al. Mass Spectrometric Comparison of HPV-Positive and HPV-Negative Oropharyngeal Cancer. Cancers (Basel). 2020,12(6). doi: 10.3390/cancers12061531Read this paper
- Liang R, Weigand I, Lippert J, et al. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Front Endocrinol (Lausanne). 2020,11:219. doi: 10.3389/fendo.2020.00219Read this paper
- Porubsky S, Jessup P, Kee D, et al. Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma. Virchows Arch. 2020,476(2):323-327. doi: 10.1007/s00428-019-02644-3Read this paper
- Lechner A, Schlößer HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncoimmunology. 2019,8(3):1535293. doi: 10.1080/2162402X.2018.1535293Read this paper



